Pharmacokinetic studies and human absorbed dose estimation of 68Ga-[4 [[[bis [phosphonomethyl]] carbamoyl] methyl]-7,10-bis[carboxymethy l] -1,4,7,10 -tetraazacyclododec-1-yl] acetic acid

Background: in this study, human absorbed dose of a newly introduced bone imaging agent, 68Ga-[4-[[[bis[phosphonomethyl]]carbamoyl]methyl]-7,10-bis [carboxymethyl]-1,4,7,10-tetraazacyclododec-1-yl] acetic acid [68Ga-BPAMD], was estimated based on the rats data

Materials and Methods: 68Ga was obtained from the 68Ge/68Ga generator and it's radionuclidic and radiochemical purities were investigated. 68Ga-BPAMD complex was prepared at optimal conditions and the radiochemical purity was studied using instant thin layer chromatography [ITLC] method. The final preparation was injected to the normal rats and the biodistribution of the complex was followed up to 120 min post injection. The accumulated activity for animal organs was calculated. Finally, the human absorbed dose of the complexes was estimated by RADAR Method

Results: 68Ga-BPAMD complex was prepared in high radiochemical purity [>99%, ITLC] at optimal conditions. The biodistribution of the complex demonstrated that the main remained radioactivity would considerably accumulate into the bones. The results showed the highest amounts of absorbed dose on the bone surface [0.253 mGy/MBq] and in the bone marrow [0.250 mGy/MBq], while the other organs would receive an insignificant absorbed dose after injection of the 68Ga-BPAMD complex

Conclusion: the comparison of dosimetric results for 68Ga-BPAMD with other complexes shows this complex is a safer agent for bone scanning. This property as well as other characteristics such as the high resolution images of the positron emission tomography [PET] scanning and the availability of 68Ga in the form of 68Ge/68Ga generator, make this complex as a suitable agent for PET bone imaging

Association between the severity of angiographic coronary artery disease and paraoxonase-1 promoter gene polymorphism T[-107] C in Iranian population

The oxidation of low-density lipoproteins and cell membrane lipids is believed to play an integral role in the development of fatty streak lesions, an initial step in coronary artery disease [CAD]. Paraoxonase-1 [PON1] is an enzyme associated with the high-density lipoprotein [HDL] particle. PON1 protects LDL from oxidative modification by hydrolyzing lipid peroxides, suggestive of a role for PON1 in the development of CAD. The present study tested the hypothesis that Paraoxonase-1 promoter polymorphism T[-107]C could be a risk factor for severity of CAD in Iranian population. Paraoxonase-1 promoter genotypes were determined in 300 consecutive subjects [> 40 years old] who underwent coronary angiography [150 subjects with >50% stenosis served as cases [CAD+] and 150 subjects with < 20% stenosis served as controls [CAD-]]. PON1 promoter genotypes were determined by PCR and BSTU1 restriction enzyme digestion. CAD+ Subjects did not show any significant differences in the distribution of PON1 promoter genotypes as compared to CAD- Subjects [P = 0.075]. However the analysis of PON1 promoter genotypes distribution showed a higher percentage of [-107] TT among CAD+ compared with CAD- [P = 0.027]. After controlling for other risk factors, the T[- 107]C polymorphism had interaction with age [P = 0.012], but did not show any interaction with other risk factors such as BMI, gender, smoking, diabetes, level of HDL-C, LDL-C, triglyceride and Total cholesterol. These data suggest that the TT genotype may represent a genetic risk factor for Coronary artery disease in Iranian population

[Production, formulation, quality control and primary biological studies of [18F]KF for skeletal PET scanning]

[[18]F]KF, considered as a reference standard for positron emission tomography of the skeletal system, was produced by the bombardment of enriched water [[18O]H2O>95%] with high energy protons in NRCAM cyclotron. After the extraction of fluoride from enriched water as KF, and passing it through microbial filter and fine adjustment of acidity and osmolality, it was converted into an injectable form. Pre-clinical investigations and biological controls were performed to determine radioisotope distribution in laboratory rats, thus suitable information was gathered for imaging in humans. This radiopharmaceutical was proved to be quite safe and of high quality as a result of testing in laboratory rats